Acute Graft-Versus-Host Disease, Prophylaxis and Therapy

Abstract

Graft-versus host disease is one of the major causes of death in patients undergoing allogeneic hematopoietic stem cell transplantation. Major contributing factors to severity of graft-versus host disease include HLA mismatch, conditioning regimen intensity, age of donor and recipient, source of stem cell, and donor type. Strategies and clinical trials are ongoing to reduce the incidence of graft-versus host disease, and to improve on the survival outcome of patients with graft-versus host disease, Research efforts continue to develop new ways of identification, prevention, and treatment for graft versus host disease. In addition, efforts are also being made to incorporate biomarker for the early detection of graft versus host disease. In addition, strategies utilizing monoclonal antibodies and cytokines are being tested as potential therapeutic options. Here we provide evidence for recommended regimens for graft versus host disease, prophylaxis and treatment.

The P2X7 Receptor Antagonist AZ10606120 Does Not Alter Graft-Versus-Host Disease Development and Increases Serum Human Interferon-γ in a Humanized Mouse Model

“…GVHD arises when donor (graft) T cells mount an inflammatory immune response against the recipient (host), damaging target tissues including the liver, skin, and gastrointestinal (GI) tract [2]. Despite advances in the understanding of GVHD pathogenesis there is no effective treatment [3], highlighting the need for new therapies.…”